Topical therapy in acne.
The majority of acne patients will receive a topical treatment either as monotherapy or in combination with a systemic drug therapy depending on the severity of the disease. The currently available topical agents affect at least one of the four main pathogenetic factors responsible for the development of acne, i.e. hyperkeratosis, microbial colonization, immune response and inflammation. Retinoids, azelaic acid, benzoyl peroxide and topical antibiotics represent the spectrum of the established and proven topical agents. Presumably, antiandrogenic agents will soon be available for topical use to treat the important factor of seborrhea. In general, by combining topical agents, their potency can be enhanced and toxicity diminished. Unfortunately, bacterial resistances are beginning to emerge as a significant problem.
Gollnick
H
H
Department of Dermatology and Venereology, Otto-von-Guericke University, Magdeburg, Germany. harald.gollnick@medizin.uni-magdeburg.de
Schramm
M
M
D000152:Acne Vulgaris / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000382:microbiology; D000279:Administration, Cutaneous; D000726:Androgen Antagonists / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D001419:Bacteria / Q000187:drug effects; D001585:Benzoyl Peroxide / Q000008:administration & dosage; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D003879:Dermatologic Agents / Q000008:administration & dosage*; D003998:Dicarboxylic Acids / Q000008:administration & dosage; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage; D007642:Keratosis / Q000188:drug therapy; D012176:Retinoids / Q000008:administration & dosage
D000726:Androgen Antagonists; D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D003998:Dicarboxylic Acids; D007641:Keratolytic Agents; D012176:Retinoids; C010038:azelaic acid; D001585:Benzoyl Peroxide